Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) Jumped 10% On superbug exposure in Los Angeles Print E-mail
By Marilyn Mullen   
Thursday, 19 February 2015 12:07
Shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) soared as much as 10%% premaron Thursday  in apparent response to the
exposure of up to 181 patients at UCLA Medical Center to carbapenem-resistant enterobacteriaceae (CRE), a drug-resistant superbug.
Read more...
 
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) Shares Fall 10% On Weak fourth quarter Earnings Print E-mail
By Josh Gee   
Tuesday, 17 February 2015 15:53
Shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) are down $10 or $8.30% to $108.60 on hefty volume after the

Error. Page cannot be displayed. Please contact your service provider for more details. (32)

company posted a worse than expected fourth quarter results this morning.
Read more...
 
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) Tumbled To New Low As FDA Puts Hold on Phase 2 clinical trial evaluating PBT2 Print E-mail
By Josh Gee   
Friday, 13 February 2015 16:20
Shares of Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) tumbled on Friday and were recently down 53 cents or 32.32% to $1.11 after hitting new low of $1.07 earlier in the session.
Read more...
 
Advaxis, Inc. (NASDAQ:ADXS) Surges 9% On collaboration with Incyte Corporation Print E-mail
By Marilyn Mullen   
Wednesday, 11 February 2015 15:25
Shares of Advaxis, Inc. (NASDAQ:ADXS) jumped 9% to $7.70 after the company entered into a clinical trial collaboration with Incyte Corporation (NASDAQ:INCY) to assess the combination of Advaxis's Lm-LLO cancer immunotherapy candidate, ADXS-HPV, with Incyte's epacadostat, an investigational oral indoleamine 2,3-dioxygenase 1 (IDO01) inhibitor.
Read more...
 
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Gains 35% On Phase 3 Trial Update Print E-mail
By Josh Gee   
Tuesday, 10 February 2015 15:49
Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) jumped a whopping 35% to $3.53 this afternoon on huge volume of 13.04 million shares – 20X its average volume as the company announced that its Phase 3 trial assessing blisibimod for the treatment of patients with systemic lupus erythematosus will continue to completion as planned. Patient enrollment should be finished by mid-year.
Read more...
 
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s Shares Rebound On Positive Development Print E-mail
By William Kent   
Monday, 09 February 2015 17:21
The shares of Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) jumped as much as 15% earlier in the session after the company’s HCV-1 regimen achieves 100% SVR12 at six weeks.
Read more...
 
Immunomedics, Inc’s (NASDAQ:IMMU) Shares tumbled over 15% As Second Quarter’s Loss Widens Print E-mail
By David Fowler   
Thursday, 05 February 2015 13:26
Shares of Immunomedics, Inc.(NASDAQ:IMMU) are under heavy selling pressure on Thursday and tumbled as much as 15.50% to $4.12 following the company has reported second-quarter loss.
Read more...
 
NephroGenex Inc(NASDAQ:NRX) received positive Scientific Advice from the European Medicines Agency For Phase 3 program Print E-mail
By Marilyn Mullen   
Friday, 09 January 2015 16:18
NephroGenex Inc. (NASDAQ:NRX) has announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin® in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment.
Read more...
 
Galectin Therapeutics Inc (NASDAQ:GALT) Gains 40% On GR-MD-02’s Phase 1 Results Print E-mail
By William Kent   
Wednesday, 07 January 2015 18:37
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer had announced that final results from their Phase 1 trial showed that GR-MD-02 had an effect on a serum biomarker and liver stiffness that suggest a potential for therapeutic effect on fibrosis that warrants further exploration.
Read more...
 
Minerva Neurosciences Inc (NASDAQ:NERV) Hits An All Time High After The Positive development Print E-mail
By William Kent   
Tuesday, 06 January 2015 14:27
Minerva Neurosciences Inc. (NASDAQ:NERV) shares soared as much as 40% and hit a new high of $10 after the company has announced that the results from a Primomed non-human primate study showed that treatment with an analog of MIN-301, the company's investigational neuregulin-1 compound, has resulted in improvements in a range of symptoms associated with Parkinson's disease in primates.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 9 of 12

Newsletter

BMR:1